Novonesis (Novozymes) B Class B

NSIS B: XCSE (DNK)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|k@LOCK|T!>LOCK|X&Vsj$t

Novonesis Earnings: Solid Organic Sales Growth Overshadowed by Margin Miss

Novonesis reported second-quarter organic sales growth of 8% and adjusted EBITDA margin of 36.4%. The margin was 130 basis points below company-complied consensus, sending shares 6% lower in early trading. The company narrowed its 2025 guidance range and released 2030 targets.

Sponsor Center